CYP3A4 and breast cancer: Antunes et al. 75 also explored the influence of the CYP3A4*22 defective variant and CYP3A4 phenotype derived from the (omeprazole)/(omeprazole sulfone) plasma concentration ratio on tamoxifen metabolism in breast cancer patients.